Abstract
MS-209, a quinolone-derived sphingomyelin synthase inhibitor that blocks P-glycoprotein and multidrug resistance-associated protein-1, is under development by Schering for the potential treatment of multidrug resistant tumors. By March 2003, phase II trials in breast cancer and non-small-cell lung cancer had been initiated.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials, Phase II as Topic
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Quinolines / chemistry
-
Quinolines / pharmacology
-
Quinolines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Quinolines
-
dofequidar